SUBJECT INDEX 



1263 



Tumors, chorioepithelioma induced by 

 X rays, 1169 

 chromosome abnormalities in. 338 

 embryoma, 1158 

 endothelioma, 1157, 1169, 1184 

 hemangioendothelioma, 1157, 1160, 



1169, 1176, 1184 

 incidence of, in painters of radioactive 



watch dials, 1158, 1182-1183 

 inhibition of "takes," 339 

 lymphoma (see Leukemia) 

 mammary, 1153, 1161, 1164, 1172- 

 1174, 1188 

 milk agent, 1173 

 neoplasms (see Carcinogenesis; Car- 

 cinogenic agents; specific sites) 

 osteosarcoma, 1111 

 papilloma, 1175 

 plasmocytoma, induction by meso- 



thorium, 1157 

 radiosensitivity of, 929 

 regression of, 325, 339 

 sarcoma (see specific animals and sites) 

 Turbidity of plasma, 974-975 

 Two-hit aberrations, 723 

 Tyndall effect, 119 

 Tyrosine, 292, 293, 296 



dissociation of hydroxyl group, 293 

 effect of alpha radiation on, 271 



U 



Ulcers, intestinal, 983 

 Ultraviolet radiation, 362, 390, 399 

 action spectrum for mutation, 540, 541, 



545 

 and chromosome changes, 531-535, 738 

 chromosome effects, 738, 814 

 cleavage furrow, change in position, 



815. 816 

 in combination with X rays, 738 

 and deletions, 532, 533 

 and dominant lethal mutations, 532 

 energy absorption in tissues, 764 

 excitations, 539 

 and inversions, 533 

 lethal effect on cells, 816. 817 

 mitotic effects (see Mitotic effects) 

 mutagenesis, by irradiation of medium, 



548-552 

 repair and enhancement in, 542-548 

 and mutation, 504, 592-595 



intensity, 538 

 nucleolar spheration, 816 

 and point mutations, 531-542 

 spindle effects, 814 

 and terminal deletions, 532 

 and translocations, 532, 533 

 (See also Light) 



Uranium, 295, 574 

 Uranyl nitrate, 575 

 Urea of blood, 973, 989 

 Urease, 299 

 Urethane, 922, 937, 946 



ethyl, 416, 424 

 Uric acid, of blood, 925, 973, 1000 



of liver, 988 

 Uricemia, 925 

 Urinary bladder, 1129 

 Urine composition, 989 

 Urobilinogen, 988 



Urogenital-system abnormalities follow- 

 ing prenatal irradiation, 886-888, 

 892, 896-897, 907, 909 

 Uterus, 1117, 1118 



carcinogenesis in, 1151, 1153, 1174- 

 1175 



V 



Vacuolization of cartilage cells, 1113 

 Vagina, 1117, 1118 

 Vagotomy, 980-981, 985 

 van der Waals force, 32 

 Variability, biological, 27 

 Variance, 80 



Vascular calcification and radium, 1122 

 Vascular changes in skin, 1121 

 Vascular damage, 966 

 Vascular fragility, 968, 979 

 Vascular permeability, 978-979 

 Vascular thrombosis, 967 

 Vascularity and radiosensitivity, 940 

 Velocity, sedimentation, 295 

 Velocity gradient, 289 

 Vertebral-column abnormalities follow- 

 ing prenatal irradiation, 884, 887, 

 902, 906-907, 909 

 Viability and mutations, 395, 853-856 

 Viability effects, cell, 804-810, 816-817 

 chromosome losses and, 807, 808 

 degenerative changes described, 804- 



807 

 DNA formation and, 808 

 dosage rate and, 810 

 kind of radiation and, 809, 810, 816, 

 817 

 a rays, 810 

 j3 rays, 809 

 7 rays, 809, 810 

 neutrons, 809 

 ultraviolet radiation, 816 

 X rays, 809 

 mitotic stage and, 805, 806 

 radiosensitivities of different kinds 



of cells, 808 

 temperature and, 810, 816 

 in vivo and in vitro, 806 



